Targets in MPNs and potential therapeutics

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Philadelphia-negative classical myeloproliferative neoplasms (MPNs), including Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Primary Myelofibrosis (PMF), originate from hematopoietic stem cells (HSCs).
• Key driver mutations in MPNs are located in specific exons of the JAK2, MPL/TPOR, and CALR genes, directly promoting clonal myeloproliferation and defining the MPN phenotype.
• These mutations lead to an overproduction of erythrocytes, platelets, and leukocytes in peripheral blood.

Purpose of the Study:

• To explore the factors contributing to the complexity and heterogeneity of MPN clinical phenotypes beyond driver mutations.
• To identify potential therapeutic targets by understanding the diverse modulators of MPN disease progression.

Main Methods:

• Analysis of MPN driver mutations in JAK2, MPL/TPOR, and CALR genes.
• Investigation of additional somatic mutations, including those affecting epigenetic regulators and spliceosomes.
• Evaluation of mutant allele burdens, clonal architecture, and signaling pathways downstream of driver mutations.

Main Results:

• MPN phenotypes are not solely determined by driver mutations (JAK2, MPL/TPOR, CALR).
• Additional somatic mutations, allele burden, clonal complexity, and germ-line variants significantly modulate MPN clinical presentation.
• The bone marrow microenvironment and chronic inflammation interact with neoplastic clones, influencing disease course.

Conclusions:

• The heterogeneity of MPN phenotypes is influenced by a complex interplay of genetic and non-genetic factors.
• Understanding these additional modulators is crucial for predicting MPN clinical course.
• These factors represent potential therapeutic targets for managing MPN complexity.